Table 4 Cox regression analysis of the total-region TLS area and density in subgroups (n = 114)
Subgroup | High TLS area | High TLS density | ||||
|---|---|---|---|---|---|---|
HR (95% CI) | P value | HR (95% CI) | P value | |||
Age | <60 | 0.638 (0.2–2.2) | 0.472 | 0.242 (0.1–1.2) | 0.044 | |
≥60 | 0.339 (0.1–1.5) | 0.094 | 0.301 (0.1–1.3) | 0.058 | ||
Sex | Male | 0.27 (0.1–0.9) | 0.016 | 0.146 (0-0.7) | 0.002 | |
Female | 0.634 (0.2–0.4) | 0.488 | 0.41 (0.1–1.9) | 0.214 | ||
cTNM | Stage II | 1.095 (0.1–17.6) | 0.949 | 2.494 (0.2–39.9) | 0.525 | |
Stage III | 0.281 (0.1–0.8) | 0.008 | 0.135 (0-0.6) | <0.001 | ||
CEA | High | 0.615 (0.2–1.9) | 0.369 | 0.37 (0.1–1.6) | 0.131 | |
Low | 0.226 (0–1) | 0.025 | 0.218 (0–1) | 0.022 | ||
CA199 | High | 0 (0-Inf) | 0.005 | 0.19 (0-1.5) | 0.045 | |
Low | 0.708 (0.3–1.9) | 0.476 | 0.312 (0.1–1.1) | 0.036 | ||
MRF | Positive | 0.531 (0.1-2) | 0.323 | 0.207 (0-1.6) | 0.062 | |
Negative | 0.248 (0.1–1.1) | 0.03 | 0.235 (0.1-1) | 0.023 | ||
EMVI | Positive | 0.417 (0.1–2.1) | 0.257 | 0 (0-Inf) | 0.033 | |
Negative | 0.379 (0.1–1.1) | 0.052 | 0.325 (0.1-1) | 0.022 | ||
LN | Yes | 0.322 (0-2.7) | 0.24 | 0 (0-Inf) | 0.131 | |
No | 0.391 (0.1-1) | 0.041 | 0.308 (0.1–0.9) | 0.015 | ||
Efficacy | Response | 0.324 (0.1–1.2) | 0.072 | 0.29 (0.1–1.1) | 0.046 | |
Non-response | 0.76 (0.2–2.6) | 0.651 | 0.373 (0-2.8) | 0.263 | ||
TRG | Yes | 0.439 (0.1–0.7) | 0.2 | 0.353 (0.1–1.3) | 0.099 | |
Partial | 0 (0-Inf) | 0.007 | 0.333 (0-2.7) | 0.24 | ||
None | 1.087 (0.3-4) | 0.9 | 0 (0-Inf) | 0.133 | ||
Postoperative adjuvant chemotherapy | Yes | 0.4 (0.1–1.4) | 0.116 | 0.337 (0.1–1.2) | 0.060 | |
No | 0.302 (0.1–1.1) | 0.042 | 0.14 (0-1.1) | 0.012 | ||
Postoperative adjuvant radiotherapy | Yes | 0.993 (0.1–11) | 0.995 | 0 (0-Inf) | 0.294 | |
No | 0.319 (0.1–0.8) | 0.009 | 0.245 (0.1–0.7) | 0.002 | ||